The portfolio is complemented by Synthecure, a synthetic bone substitute based on calcium sulphate that is authorised in the USA. Innotere’s products are marketed under the heracure brand. These include a ready-to-use paste and 3D-printed moulded components for non-infected and non-weight-bearing bone defects. Both product families are certified in accordance with the European Medical Devices Regulation. Direct sales began in early 2026 in selected markets and are set to be gradually expanded internationally. Heraeus will continue to operate the Radebeul site as a development and production centre, integrating it with its headquarters in Wehrheim. In doing so, the company is expanding its business – which has hitherto focused heavily on bone cements and infection management – to include regenerative applications, whilst strengthening its presence in the field of resorbable biomaterials.
News from “Heraeus Medical GmbH” dated 9 September 2026